Kura Oncology Statistics
Total Valuation
Kura Oncology has a market cap or net worth of $563.60 million. The enterprise value is -$88.22 million.
Important Dates
The last earnings date was Thursday, May 1, 2025, after market close.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kura Oncology has 86.57 million shares outstanding. The number of shares has increased by 12.88% in one year.
| Current Share Class | 80.78M |
| Shares Outstanding | 86.57M |
| Shares Change (YoY) | +12.88% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 0.80% |
| Owned by Institutions (%) | 70.29% |
| Float | 59.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.31 |
| Forward PS | 7.40 |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | 4.98 |
| P/OCF Ratio | 4.95 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.07, with a Debt / Equity ratio of 0.05.
| Current Ratio | 8.07 |
| Quick Ratio | 7.88 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.18 |
| Interest Coverage | -126.91 |
Financial Efficiency
Return on equity (ROE) is -41.84% and return on invested capital (ROIC) is -28.07%.
| Return on Equity (ROE) | -41.84% |
| Return on Assets (ROA) | -19.60% |
| Return on Invested Capital (ROIC) | -28.07% |
| Return on Capital Employed (ROCE) | -31.11% |
| Revenue Per Employee | $354,120 |
| Profits Per Employee | -$947,328 |
| Employee Count | 192 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kura Oncology has paid $2.24 million in taxes.
| Income Tax | 2.24M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.44% in the last 52 weeks. The beta is 0.50, so Kura Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -68.44% |
| 50-Day Moving Average | 6.86 |
| 200-Day Moving Average | 12.97 |
| Relative Strength Index (RSI) | 48.08 |
| Average Volume (20 Days) | 1,489,419 |
Short Selling Information
The latest short interest is 8.68 million, so 10.02% of the outstanding shares have been sold short.
| Short Interest | 8.68M |
| Short Previous Month | 8.80M |
| Short % of Shares Out | 10.02% |
| Short % of Float | 14.51% |
| Short Ratio (days to cover) | 5.87 |
Income Statement
In the last 12 months, Kura Oncology had revenue of $67.99 million and -$181.89 million in losses. Loss per share was -$2.09.
| Revenue | 67.99M |
| Gross Profit | -87.36M |
| Operating Income | -203.44M |
| Pretax Income | -181.75M |
| Net Income | -181.89M |
| EBITDA | -202.59M |
| EBIT | -203.44M |
| Loss Per Share | -$2.09 |
Full Income StatementBalance Sheet
The company has $658.19 million in cash and $19.35 million in debt, giving a net cash position of $638.84 million or $7.38 per share.
| Cash & Cash Equivalents | 658.19M |
| Total Debt | 19.35M |
| Net Cash | 638.84M |
| Net Cash Per Share | $7.38 |
| Equity (Book Value) | 364.41M |
| Book Value Per Share | 4.51 |
| Working Capital | 634.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $111.23 million and capital expenditures -$680,000, giving a free cash flow of $110.55 million.
| Operating Cash Flow | 111.23M |
| Capital Expenditures | -680,000 |
| Free Cash Flow | 110.55M |
| FCF Per Share | $1.28 |
Full Cash Flow StatementMargins
Gross margin is -128.48%, with operating and profit margins of -299.22% and -267.52%.
| Gross Margin | -128.48% |
| Operating Margin | -299.22% |
| Pretax Margin | -264.22% |
| Profit Margin | -267.52% |
| EBITDA Margin | -297.96% |
| EBIT Margin | -299.22% |
| FCF Margin | 162.60% |